Related Experiment Video
Updated: Aug 8, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Elevated plasma adiponectin in humans with genetically defective insulin receptors
1Department of Clinical Biochemistry, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2QR, United Kingdom. rks16@cam.ac.uk
Context:
Adiponectin has been suggested to play a role in the etiopathogenesis of at least some forms of insulin resistance, in part based on a strong correlation between plasma levels of adiponectin and measures of insulin sensitivity.
Objective:
The objective of the study was to establish whether this relationship is maintained at extreme levels of insulin resistance.
Design/Setting:
This was a cross-sectional study in a university teaching hospital of subjects recruited from the United Kingdom and the United States.
Participants:
Participants included 75 subjects with a range of syndromes of severe insulin resistance and 872 nondiabetic controls.
Outcome Measures:
Fasting plasma insulin, adiponectin, and leptin were measured.
Results:
Unexpectedly, subjects with mutations in the insulin receptor, despite having the most severe degree of insulin resistance, had elevated plasma adiponectin [median 24.4 mg/liter; range 6.6-36.6 (normal adult range for body mass index 20 kg/m(2) = 3-19 mg/liter)], whereas all other subjects had low adiponectin levels (median 2.0 mg/liter; range 0.12-11.2). Plasma leptin in all but one subject with an insulin receptoropathy was low or undetectable [median 0.5 ng/ml; range 0-16: normal adult range for body mass index of < 25 kg/m(2) = 2.4-24.4 (female) and 0.4-8.3 ng/ml (male)].
Conclusions:
We conclude that the relationship between plasma adiponectin and insulin sensitivity is complex and dependent on the precise etiology of defective insulin action and that the combination of high plasma adiponectin with low leptin may have clinical utility in patients with severe insulin resistance as a marker of the presence of a genetic defect in the insulin receptor.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Type II Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Cell Specific Gene Expression
